The board of Valiant Holding AG ( VTX:VATN ) has announced that it will be paying its dividend of CHF6.00 on the 20th...

If you are on the fence about Valiant Holding stock, you are definitely not alone lately. After a strong start to the year, the share price continues to invite debate, closing most recently at 130.0. Over the past year, Valiant has delivered an impressive 37.0% return, and even looking back five years, the stock has surged by a remarkable 111.4%. While the last seven days saw a modest gain of 1.4%, a slight dip of -1.1% over the past month shows how sentiment can shift in the short term. A...

Valiant Holding (SWX:VATN) has been attracting the attention of investors lately, and it is easy to see why. When a stock moves for reasons that are not necessarily headline grabbing, it can often be a signal that underlying factors are shifting or that the market is quietly adjusting its expectations. Whether you are already holding shares or simply considering your next move, changes in sentiment like this tend to raise questions about what might be driving the trend. Looking at the bigger...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.